News
Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...
Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...
A study published in the journal Cell marks the first reported instance of generative AI designing synthetic molecules that ...
Detailed price information for Ernexa Therapeutics Inc (ERNA-Q) from The Globe and Mail including charting and trades.
Research into treatment using induced pluripotent stem (iPS) cells has been generating positive results one after another.
Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) ...
Congratulations to Karl-Johan Malmberg, who has been awarded King Olav V's Cancer Research Prize for 2025. The prize is ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster ...
The development of novel therapeutics offers great hope for the fight against widespread diseases such as cancer, but they ...
Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results